GSA Capital Partners LLP Acquires New Stake in ResMed Inc. (NYSE:RMD)

GSA Capital Partners LLP bought a new stake in ResMed Inc. (NYSE:RMDFree Report) in the 3rd quarter, Holdings Channel reports. The institutional investor bought 1,680 shares of the medical equipment provider’s stock, valued at approximately $410,000.

A number of other institutional investors and hedge funds also recently modified their holdings of RMD. Entropy Technologies LP purchased a new position in ResMed in the 3rd quarter worth approximately $1,872,000. Apollon Wealth Management LLC raised its position in shares of ResMed by 15.1% during the 3rd quarter. Apollon Wealth Management LLC now owns 1,451 shares of the medical equipment provider’s stock valued at $354,000 after acquiring an additional 190 shares in the last quarter. Venturi Wealth Management LLC lifted its stake in ResMed by 55.7% during the third quarter. Venturi Wealth Management LLC now owns 341 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 122 shares during the last quarter. Ashton Thomas Securities LLC bought a new position in ResMed during the third quarter worth $34,000. Finally, State of New Jersey Common Pension Fund D lifted its stake in ResMed by 1.0% during the third quarter. State of New Jersey Common Pension Fund D now owns 53,893 shares of the medical equipment provider’s stock worth $13,156,000 after purchasing an additional 524 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on RMD. Needham & Company LLC restated a “hold” rating on shares of ResMed in a research note on Friday, October 25th. Bank of America lifted their price target on ResMed from $240.00 to $270.00 and gave the stock a “buy” rating in a research report on Thursday, September 26th. Royal Bank of Canada boosted their price objective on ResMed from $224.00 to $232.00 and gave the company a “sector perform” rating in a research report on Friday, October 25th. Baird R W raised ResMed to a “strong-buy” rating in a research note on Tuesday, September 24th. Finally, StockNews.com raised ResMed from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. One analyst has rated the stock with a sell rating, five have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $225.70.

View Our Latest Stock Report on RMD

ResMed Trading Up 0.8 %

Shares of RMD stock opened at $243.60 on Friday. The company has a current ratio of 2.92, a quick ratio of 1.91 and a debt-to-equity ratio of 0.13. The stock has a market cap of $35.76 billion, a P/E ratio of 32.26, a price-to-earnings-growth ratio of 1.73 and a beta of 0.69. The stock has a 50 day simple moving average of $241.96 and a 200 day simple moving average of $224.23. ResMed Inc. has a 1 year low of $151.95 and a 1 year high of $260.49.

ResMed (NYSE:RMDGet Free Report) last released its earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.17. The firm had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.19 billion. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The company’s quarterly revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the company earned $1.64 earnings per share. On average, research analysts predict that ResMed Inc. will post 9.28 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th will be given a dividend of $0.53 per share. The ex-dividend date is Thursday, November 7th. This represents a $2.12 dividend on an annualized basis and a yield of 0.87%. ResMed’s dividend payout ratio (DPR) is currently 28.08%.

Insider Transactions at ResMed

In other news, Director Witte Jan De sold 796 shares of ResMed stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total transaction of $198,052.76. Following the completion of the sale, the director now directly owns 6,723 shares of the company’s stock, valued at approximately $1,672,749.63. The trade was a 10.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Kaushik Ghoshal sold 5,000 shares of ResMed stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $252.56, for a total transaction of $1,262,800.00. Following the completion of the transaction, the insider now owns 21,788 shares in the company, valued at approximately $5,502,777.28. The trade was a 18.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 62,174 shares of company stock valued at $14,882,278 in the last 90 days. 0.71% of the stock is currently owned by corporate insiders.

About ResMed

(Free Report)

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.

Featured Stories

Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMDFree Report).

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.